In addition, treatment with anti-CXCR3 in combination with bintrafusp alfa was indistinguishable from either the isotype controls (survival P = 0.3254; day 27 tumor size P = 0.4585), or anti-CXCR3 alone (survival P = 0.7416; day 27 tumor size P = 0.0723, n = 10, 13) (Fig. 7a, b), suggesting that anti-CXCR3 prevents any antitumor effect of bintrafusp alfa. This evidence concerns the gene CXCR3 and neoplasm.